{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T15:29:39Z","timestamp":1780586979917,"version":"3.54.1"},"reference-count":35,"publisher":"Elsevier BV","issue":"37","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,8]],"date-time":"2024-08-08T00:00:00Z","timestamp":1723075200000},"content-version":"am","delay-in-days":373,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004823","name":"Nagoya University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004823","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP21nf0101635"],"award-info":[{"award-number":["JP21nf0101635"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["22H03299"],"award-info":[{"award-number":["22H03299"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001700","name":"Ministry of Education, Culture, Sports, Science and Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.vaccine.2023.07.035","type":"journal-article","created":{"date-parts":[[2023,7,22]],"date-time":"2023-07-22T08:35:53Z","timestamp":1690014953000},"page":"5447-5453","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Effectiveness of COVID-19 vaccines against infection in Japan: A test-negative study from the VENUS study"],"prefix":"10.1016","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6868-4195","authenticated-orcid":false,"given":"Yudai","family":"Tamada","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8769-8955","authenticated-orcid":false,"given":"Kenji","family":"Takeuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taro","family":"Kusama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megumi","family":"Maeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumiko","family":"Murata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Osaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruhisa","family":"Fukuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2023.07.035_b0005","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2023.07.035_b0010","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2023.07.035_b0015","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/S0140-6736(21)00432-3","article-title":"Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials","volume":"397","author":"Voysey","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2023.07.035_b0020","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1056\/NEJMoa2108891","article-title":"Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant","volume":"385","author":"Lopez Bernal","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2023.07.035_b0025","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.ijid.2021.11.009","article-title":"Real-world effectiveness of COVID-19 vaccines: a literature review and meta-analysis","volume":"114","author":"Zheng","year":"2022","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.vaccine.2023.07.035_b0030","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1186\/s12916-022-02397-y","article-title":"Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern: a systematic review and meta-analysis","volume":"20","author":"Zeng","year":"2022","journal-title":"BMC Med"},{"key":"10.1016\/j.vaccine.2023.07.035_b0035","unstructured":"Ministry of Health Labour and Welfare of Japan. Situation report on COVID-19. <https:\/\/www.mhlw.go.jp\/stf\/covid-19\/kokunainohasseijoukyou_00006.html>. [accessed May 30, 2023]."},{"key":"10.1016\/j.vaccine.2023.07.035_b0040","unstructured":"Digital Agency of Japan. Daily achievements of COVID-19 vaccine. <https:\/\/info.vrs.digital.go.jp\/dashboard>. [accessed May 30, 2023]."},{"key":"10.1016\/j.vaccine.2023.07.035_b0045","article-title":"Effectiveness of mRNA COVID-19 vaccines against symptomatic SARS-CoV-2 infections during the Delta variant epidemic in Japan: vaccine effectiveness real-time surveillance for SARS-CoV-2 (VERSUS)","author":"Maeda","year":"2022","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2023.07.035_b0050","article-title":"COVID-19 vaccine effectiveness against symptomatic SARS-CoV-2 infection during Delta-dominant and Omicron-dominant periods in Japan: a multi-center prospective case-control study (FASCINATE study)","author":"Arashiro","year":"2022","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2023.07.035_b0055","doi-asserted-by":"crossref","first-page":"6179","DOI":"10.1016\/j.vaccine.2022.08.069","article-title":"Development and application of a Japanese vaccine database for comparative assessments in the post-authorization phase: the Vaccine Effectiveness, Networking, and Universal Safety (VENUS) study","volume":"40","author":"Ishiguro","year":"2022","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2023.07.035_b0060","article-title":"The Longevity Improvement & Fair Evidence (LIFE) Study: overview of the study design and baseline participant profile","author":"Fukuda","year":"2022","journal-title":"J Epidemiol"},{"key":"10.1016\/j.vaccine.2023.07.035_b0065","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1056\/NEJMe2113151","article-title":"Covid-19 vaccine effectiveness and the test-negative design","volume":"385","author":"Dean","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2023.07.035_b0070","unstructured":"Ministry of Health Labour and Welfare of Japan. Results of genomic surveillance for COVID-19. <https:\/\/www.mhlw.go.jp\/stf\/seisakunitsuite\/newpage_00061.html>. [accessed May 30, 2023]."},{"key":"10.1016\/j.vaccine.2023.07.035_b0075","article-title":"Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study","volume":"373","author":"Lopez Bernal","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.vaccine.2023.07.035_b0080","unstructured":"Ministry of Health Labour and Welfare of Japan. Health Center Real-time Information-sharing System on COVID-19 (HER-SYS). <https:\/\/www.mhlw.go.jp\/stf\/seisakunitsuite\/bunya\/0000121431_00181.html>. [accessed May 30, 2023]."},{"key":"10.1016\/j.vaccine.2023.07.035_b0085","unstructured":"Digital Agency of Japan. Vaccination Record System. <https:\/\/info.vrs.digital.go.jp\/>. [accessed May 30, 2023]."},{"key":"10.1016\/j.vaccine.2023.07.035_b0090","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1038\/s41564-021-00947-3","article-title":"Antibody responses to SARS-CoV-2 vaccines in 45,965 adults from the general population of the United Kingdom","volume":"6","author":"Wei","year":"2021","journal-title":"Nat Microbiol"},{"key":"10.1016\/j.vaccine.2023.07.035_b0095","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1038\/s41591-021-01446-y","article-title":"mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in Qatar","volume":"27","author":"Chemaitelly","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.vaccine.2023.07.035_b0100","article-title":"Effectiveness of CoronaVac among healthcare workers in the setting of high SARS-CoV-2 Gamma variant transmission in Manaus, Brazil: a test-negative case-control study","volume":"1","author":"Hitchings","year":"2021","journal-title":"Lancet Reg Health Am"},{"key":"10.1016\/j.vaccine.2023.07.035_b0105","article-title":"Effectiveness of the CoronaVac vaccine in older adults during a gamma variant associated epidemic of covid-19 in Brazil: test negative case-control study","volume":"374","author":"Ranzani","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.vaccine.2023.07.035_b0110","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J Chronic Dis"},{"key":"10.1016\/j.vaccine.2023.07.035_b0115","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1038\/s41591-021-01583-4","article-title":"BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in Qatar","volume":"27","author":"Tang","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.vaccine.2023.07.035_b0120","doi-asserted-by":"crossref","unstructured":"Dinnes J, Sharma P, Berhane S, van Wyk SS, Nyaaba N, Domen J, et al. Rapid, point-of-care antigen tests for diagnosis of SARS-CoV-2 infection. Cochrane Database Syst Rev 2022;7:CD013705. 10.1002\/14651858.CD013705.pub3.","DOI":"10.1002\/14651858.CD013705.pub3"},{"key":"10.1016\/j.vaccine.2023.07.035_b0125","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.3201\/eid2809.220300","article-title":"Social and behavioral factors associated with lack of intent to receive COVID-19 vaccine, Japan","volume":"28","author":"Arashiro","year":"2022","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.vaccine.2023.07.035_b0130","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1038\/s41591-022-01699-1","article-title":"Effectiveness of COVID-19 booster vaccines against COVID-19-related symptoms, hospitalization and death in England","volume":"28","author":"Andrews","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.vaccine.2023.07.035_b0135","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1056\/NEJMoa2115481","article-title":"Duration of protection against mild and severe disease by covid-19 vaccines","volume":"386","author":"Andrews","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2023.07.035_b0140","unstructured":"Prime Minister\u2019s Office of Japan. COVID-19 Vaccines. <https:\/\/www.kantei.go.jp\/jp\/headline\/kansensho\/vaccine.html>. [accessed May 30, 2023]."},{"key":"10.1016\/j.vaccine.2023.07.035_b0145","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/s41564-021-01053-0","article-title":"Effectiveness of COVID-19 vaccines against symptomatic SARS-CoV-2 infection and severe outcomes with variants of concern in Ontario","volume":"7","author":"Nasreen","year":"2022","journal-title":"Nat Microbiol"},{"key":"10.1016\/j.vaccine.2023.07.035_b0150","doi-asserted-by":"crossref","first-page":"e623","DOI":"10.1093\/cid\/ciac106","article-title":"Comparative effectiveness of coronavirus disease 2019 (COVID-19) vaccines against the delta variant","volume":"75","author":"Risk","year":"2022","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2023.07.035_b0155","unstructured":"Israel\u2019s Ministry of Health Report. COVID-19 vaccine effectiveness against the Delta variant. <https:\/\/www.gov.il\/BlobFolder\/reports\/vaccine-efficacy-safety-follow-up-committee\/he\/files_publications_corona_two-dose-vaccination-data.pdf>. [accessed May 30, 2023]."},{"key":"10.1016\/j.vaccine.2023.07.035_b0160","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1056\/NEJMoa2118946","article-title":"Protection and waning of natural and hybrid immunity to SARS-CoV-2","volume":"386","author":"Goldberg","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2023.07.035_b0165","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/S0140-6736(22)00152-0","article-title":"Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression","volume":"399","author":"Feikin","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2023.07.035_b0170","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/s41586-021-03739-1","article-title":"Age-related immune response heterogeneity to SARS-CoV-2 vaccine BNT162b2","volume":"596","author":"Collier","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2023.07.035_b0175","unstructured":"National Institute of Infectious Diseases of Japan. Clinical practice guideline for COVID-19 test Ver. 5.1. <https:\/\/www.mhlw.go.jp\/content\/000914399.pdf>. [accessed May 30, 2023]."}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X23008563?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X23008563?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:28:45Z","timestamp":1759404525000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X23008563"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":35,"journal-issue":{"issue":"37","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["S0264410X23008563"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2023.07.035","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effectiveness of COVID-19 vaccines against infection in Japan: A test-negative study from the VENUS study","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2023.07.035","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}